NCT03866798View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

PHASE4TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

September 19, 2023

Study Completion Date

May 17, 2024

Conditions
Chronic Immune Thrombocytopenia
Interventions
BIOLOGICAL

Panzyga

Immune Globulin, intravenous, human-ifas

Trial Locations (8)

19104

Octapharma Research Site, Philadelphia

43205

Octapharma Research Site, Columbus

43606

Octapharma Research Site, Toledo

55404

Octapharma Research Site, Minneapolis

55905

Octapharma Research Site, Rochester

77030

Octapharma Research Site, Houston

95817

Octapharma Research Site, Sacramento

02903

Octapharma Research Site, Providence

Sponsors

Lead Sponsor

Octapharma
All Listed Sponsors
lead

Octapharma

INDUSTRY

NCT03866798 - Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter